IMPORTANCE An increasing number of cutaneous adverse reactions resulting from use of programmed cell death protein 1 (PD-1) inhibitors have been described, but with relatively little focus to date on the timing of these reactions.
I mmune checkpoint inhibitors, including ipilimumab, an anticytotoxic T-lymphocyte-associated protein 4 agent, and pembrolizumab and nivolumab, anti-programmed cell death protein 1 (PD-1) inhibitors, have demonstrated considerable efficacy in treating advanced melanoma and other cancers. 1 Immune-related adverse events (irAEs) are recognized complications of these medications. 1, 2 Immune-related adverse events often affect the gut, endocrine system, liver, lungs, and skin. 3 Cutaneous irAEs associated with PD-1 inhibitors occur in approximately 40% of treated patients, 4 including morbilliform eruptions, pruritus, eczema, psoriasis, lichenoid dermatitis, bullous pemphigoid, sarcoidosis, vitiligo, dermatomyositis, and lupuslike reactions. 5, 6 Although the number of PD-1 inhibitor-associated cutaneous irAEs continues to grow, the timing of these reactions has received little focus. One review suggested that cutaneous irAEs primarily develop early, within 5 weeks of treatment initiation, a time frame similar to that of conventional medication reactions. 7 In contrast, a recent meta-analysis 8 suggested that PD-1 inhibitor-associated cutaneous irAEs may have late onsets and identified eruptions occurring as long as 24 months after initiation of PD-1 inhibitor therapy.
To further examine the timing of cutaneous reactions associated with PD-1 inhibitors and confirm prior evidence that delayed reactions may occur, we studied a cohort of 17 patients presenting with diverse biopsy-proven cutaneous adverse reactions secondary to use of PD-1 inhibitors. In addition, we show that such cutaneous irAEs may occur after discontinuation of the therapy, which to our knowledge has not been reported previously.
Methods
Patients included in this retrospective observational study were referred by an oncologist for dermatologic evaluation of a skin reaction in the setting of PD-1 inhibitor treatment alone or with ipilimumab from January 1, 2014, through February 28, 2018. All eligible patients had at least 1 skin biopsy of a PD-1 inhibitor-associated cutaneous irAE interpreted at our dermatopathology laboratory, Penn Cutaneous Pathology Services. This study was approved by the institutional review board of the University of Pennsylvania, which waived the need for informed consent for this retrospective review of medical records.
We collected the following information: age at initiation of PD-1 inhibitor use, sex, type of malignant neoplasm, treatment regimen, type and onset date of cutaneous irAE, number of treatment cycles completed, and date of treatment discontinuation. The date of cutaneous irAE onset was determined by review of the medical record, defined as the first documentation of associated symptoms. Tumor response was determined based on documentation from treating oncologists. Where applicable, statistical comparisons between groups were assessed by the Kruskal-Wallis test.
Results
Seventeen patients met inclusion criteria for this study, including 12 men (65%) and 5 women (35%) (mean [SD] age, 68.6 [11.1] years) ( Table 1) . Twelve patients (71%) had metastatic melanoma, 3 (18%) had metastatic squamous cell carcinoma, and 2 (12%) had metastatic renal cell carcinoma. Eleven patients (65%) received pembrolizumab; 5 (29%), nivolumab; and 1 (6%), both medications at different times in the treatment course. Two patients (12%) treated with nivolumab received concomitant ipilimumab. Patient 10 developed 2 distinct cutaneous irAEs at different points. Nine patients (53%) had a complete response to therapy; 2 (12%), a partial response; and 6 (35%), progression of disease.
Five patients developed cutaneous irAEs within 3 months of beginning therapy. By contrast, 12 patients (71%) developed biopsy-proven irAEs 3 or more months after therapy initiation. For example, patient 17 had a markedly delayed onset of a cutaneous irAE. He received pembrolizumab for metastatic melanoma 38.0 months before the onset of painful red plaques and blisters on his palms (Figure, A) and several oral mucosal erosions. Results of biopsies of specimens taken from the palms showed a patchy inflammatory infiltrate composed of lymphocytes and eosinophils approximating the dermal-epidermal junction, with basovacuolar change and scattered dyskeratotic keratinocytes in the epidermis (Figure, B) , indicative of erythema multiforme. The eruption resolved with a course of prednisone therapy but reappeared after his next cycle of pembrolizumab therapy.
Five patients (29%) developed reactions after PD-1 inhibitor therapy was discontinued ( Table 2) . Patients discontinued PD-1 inhibitor therapy for several reasons, including complete response to therapy, progression of disease, and development of extracutaneous irAEs. Patient 6 received pembrolizumab for metastatic sinonasal mucosal melanoma and stopped therapy owing to disease progression. Two months after her last infusion (4 months after her first infusion), scaly red papules with central pseudovesicles developed on her arms, legs, hands, and feet (Figure, C) . A biopsy revealed epidermal
Key Points
Question What is the timing of onset of cutaneous immune-related adverse reactions in patients treated with programmed cell death protein 1 inhibitors?
Findings In this study of 17 patients with metastatic melanoma or carcinoma and diverse biopsy-proven adverse cutaneous reactions to programmed cell death protein 1 inhibitor treatment, skin disease developed a median of 4.2 months after drug initiation (range, 0.5-38.0 months). In several cases, the cutaneous adverse reactions appeared after the medication was discontinued.
Meaning Skin reactions associated with use of programmed cell death protein 1 inhibitors may have delayed onset, occurring even after discontinuation of the medication.
acanthosis, hyperkeratosis, and hypergranulosis, a mild lichenoid lymphocytic infiltrate approximating the dermalepidermal junction, vacuolar alteration, and focal sawtooth changes of the rete ridges, findings of a lichenoid dermatitis (Figure, D) .
A wide range of timing of onset of cutaneous irAEs was observed in our cohort (Tables 1 and 2 
Discussion
Our findings indicate that a wide range of timelines is associated with cutaneous irAEs after PD-1 inhibitor therapy. A delayed onset of cutaneous irAEs (≥3 months) is common. We also found that PD-1 inhibitor-associated cutaneous irAEs may occur after treatment discontinuation. Although skin reactions occurring after medication discontinuation cannot be definitively proven to be caused by PD-1 inhibitors, in our cohort these reactions were of the type frequently attributed to pembrolizumab and nivolumab (sarcoidosis, lichenoid dermatitis, bullous pemphigoid, and erythema multiforme). 6 That PD-1 inhibitors have lasting effects is corroborated by studies demonstrating that tumor responses are highly durable, even after stopping therapy. 10, 11 Prolonged tumor responses associated with persistence of immune reactivation and tumor targeting suggest that irAEs may appear after discontinuation of therapy as well. These characteristics are shared by other immunotherapy agents because responses to ipilimumab are simi- larly prolonged after discontinuation. 12 Although to our knowledge, cutaneous irAEs occurring after discontinuing PD-1 inhibitor therapy have not been reported previously, PD-1 inhibitor-induced colitis has been documented in patients many months after stopping therapy.
13
Our study population included only patients referred to the dermatology clinic and for whom biopsies were performed. Therefore, our times to onset are not necessarily descriptive of common treatment-associated skin irAEs of pruritus and mild morbilliform eruptions, often managed with supportive care without dermatology referral. These reactions have variable times to onset but tend to occur early during treatment.
Most of our patients had complete or partial responses to PD-1 inhibitors. Tumor responses may be associated with cutaneous irAE development, a hypothesis that has been supported by prior studies.
14 Although we did not observe any correlation between time to onset and tumor response in our study, further investigation is warranted.
The mean elimination half-life of both pembrolizumab and nivolumab is approximately 26 days, 15 but the effects of PD-1 inhibitors almost certainly last onger. Cutaneous irAEs associated with PD-1 inhibitor therapy therefore do not fit the profile of more traditional medication reactions. Therefore, it is important for dermatologists and oncologists to be aware that cutaneous irAEs may occur long after initiation of PD-1 therapy and may appear after discontinuation.
Limitations
This small, retrospective study was conducted at a single institution. The study population included only patients treated with PD-1 inhibitors referred to our clinic by oncologists and for whom biopsies were performed.
Conclusions
Diverse cutaneous irAEs may present months to years after PD-1 inhibitor therapy is initiated and even after it is stopped. Patients should be monitored for cutaneous reactions before and after discontinuing immunotherapy.
